• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

路易体轻度认知障碍的研究诊断标准:系统评价和荟萃分析。

Research diagnostic criteria for mild cognitive impairment with Lewy bodies: A systematic review and meta-analysis.

机构信息

Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.

Department of Neuroscience, Catholic University of Sacred Heart, Rome, Italy.

出版信息

Alzheimers Dement. 2023 Jul;19(7):3186-3202. doi: 10.1002/alz.13105. Epub 2023 Apr 24.

DOI:10.1002/alz.13105
PMID:37096339
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10695683/
Abstract

INTRODUCTION

Operationalized research criteria for mild cognitive impairment with Lewy bodies (MCI-LB) were published in 2020. The aim of this systematic review and meta-analysis was to review the evidence for the diagnostic clinical features and biomarkers in MCI-LB set out in the criteria.

METHODS

MEDLINE, PubMed, and Embase were searched on 9/28/22 for relevant articles. Articles were included if they presented original data reporting the rates of diagnostic features in MCI-LB.

RESULTS

Fifty-seven articles were included. The meta-analysis supported the inclusion of the current clinical features in the diagnostic criteria. Evidence for striatal dopaminergic imaging and meta-iodobenzylguanidine cardiac scintigraphy, though limited, supports their inclusion. Quantitative electroencephalogram (EEG) and fluorodeoxyglucose positron emission tomography (PET) show promise as diagnostic biomarkers.

DISCUSSION

The available evidence largely supports the current diagnostic criteria for MCI-LB. Further evidence will help refine the diagnostic criteria and understand how best to apply them in clinical practice and research.

HIGHLIGHTS

A meta-analysis of the diagnostic features of MCI-LB was carried out. The four core clinical features were more common in MCI-LB than MCI-AD/stable MCI. Neuropsychiatric and autonomic features were also more common in MCI-LB. More evidence is needed for the proposed biomarkers. FDG-PET and quantitative EEG show promise as diagnostic biomarkers in MCI-LB.

摘要

简介

2020 年发表了路易体轻度认知障碍(MCI-LB)的操作性研究标准。本系统评价和荟萃分析的目的是回顾标准中列出的 MCI-LB 的诊断临床特征和生物标志物的证据。

方法

于 2022 年 9 月 28 日在 MEDLINE、PubMed 和 Embase 上搜索相关文章。如果文章报告了 MCI-LB 中诊断特征的发生率的原始数据,则将其纳入。

结果

共纳入 57 篇文章。荟萃分析支持将当前临床特征纳入诊断标准。尽管有限,但支持纳入纹状体多巴胺能成像和 meta-碘苄胍心脏闪烁显像的证据。定量脑电图(EEG)和氟脱氧葡萄糖正电子发射断层扫描(PET)显示出作为诊断生物标志物的潜力。

讨论

现有证据在很大程度上支持当前的 MCI-LB 诊断标准。进一步的证据将有助于完善诊断标准,并了解如何在临床实践和研究中最好地应用它们。

要点

对 MCI-LB 的诊断特征进行了荟萃分析。与 MCI-AD/稳定 MCI 相比,MCI-LB 中更常见四个核心临床特征。神经精神和自主神经特征在 MCI-LB 中也更为常见。对于提议的生物标志物,需要更多的证据。FDG-PET 和定量 EEG 显示出作为 MCI-LB 诊断生物标志物的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ccb/10695683/756c3c189a52/nihms-1944285-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ccb/10695683/756c3c189a52/nihms-1944285-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ccb/10695683/756c3c189a52/nihms-1944285-f0001.jpg

相似文献

1
Research diagnostic criteria for mild cognitive impairment with Lewy bodies: A systematic review and meta-analysis.路易体轻度认知障碍的研究诊断标准:系统评价和荟萃分析。
Alzheimers Dement. 2023 Jul;19(7):3186-3202. doi: 10.1002/alz.13105. Epub 2023 Apr 24.
2
Neuropsychological test performance in mild cognitive impairment with Lewy bodies: A systematic review and meta-analysis.路易体轻度认知障碍的神经心理学测试表现:一项系统评价和荟萃分析。
Alzheimers Dement. 2025 Feb;21(2):e14450. doi: 10.1002/alz.14450. Epub 2025 Jan 10.
3
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).脑脊液tau蛋白及脑脊液tau蛋白与β淀粉样蛋白比值在轻度认知障碍(MCI)患者中用于诊断阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
4
18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代甲磺酸去甲肾上腺素的18F正电子发射断层显像用于轻度认知障碍(MCI)患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012884. doi: 10.1002/14651858.CD012884.
5
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代硼吡咯进行18F正电子发射断层显像以早期诊断轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012216. doi: 10.1002/14651858.CD012216.pub2.
6
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.用于路易体痴呆、帕金森病痴呆及帕金森病认知障碍的胆碱酯酶抑制剂
Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD006504. doi: 10.1002/14651858.CD006504.pub2.
7
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
8
Clinical judgement by primary care physicians for the diagnosis of all-cause dementia or cognitive impairment in symptomatic people.初级保健医生对有症状人群进行全因痴呆或认知障碍诊断的临床判断。
Cochrane Database Syst Rev. 2022 Jun 16;6(6):CD012558. doi: 10.1002/14651858.CD012558.pub2.
9
Progression of clinical diagnostic features and cognitive decline in mild cognitive impairment with Lewy bodies.路易体轻度认知障碍的临床诊断特征进展与认知衰退
Psychol Med. 2025 Jun 24;55:e175. doi: 10.1017/S0033291725100895.
10
Cholinesterase inhibitors for dementia with Lewy bodies.用于路易体痴呆的胆碱酯酶抑制剂。
Cochrane Database Syst Rev. 2003;2003(3):CD003672. doi: 10.1002/14651858.CD003672.

引用本文的文献

1
Early functional changes in lewy body dementia: roles of dynamics, locus coeruleus, and compensation.路易体痴呆的早期功能变化:动力学、蓝斑及代偿的作用
Alzheimers Res Ther. 2025 Aug 23;17(1):199. doi: 10.1186/s13195-025-01828-1.
2
Risk factors and predictors for Lewy body dementia: a systematic review.路易体痴呆的风险因素和预测因素:一项系统综述。
NPJ Dement. 2025;1(1):20. doi: 10.1038/s44400-025-00022-2. Epub 2025 Aug 4.
3
Quantitative electroencephalography in the diagnosis of dementia with Lewy bodies.定量脑电图在路易体痴呆诊断中的应用

本文引用的文献

1
(Dis-)Connected Dots in Dementia with Lewy Bodies-A Systematic Review of Connectivity Studies.(Dis-)连接的路易体痴呆症的点 - 连通性研究的系统综述。
Mov Disord. 2023 Jan;38(1):4-15. doi: 10.1002/mds.29248. Epub 2022 Oct 17.
2
Dementia with Lewy bodies: Impact of co-pathologies and implications for clinical trial design.路易体痴呆:共病的影响及其对临床试验设计的意义。
Alzheimers Dement. 2023 Jan;19(1):318-332. doi: 10.1002/alz.12814. Epub 2022 Oct 14.
3
Frequency, Severity, and Duration of Autonomic Symptoms in Patients of Prodromal Dementia with Lewy Bodies.
Clin Neurophysiol Pract. 2025 Jul 2;10:222-233. doi: 10.1016/j.cnp.2025.06.008. eCollection 2025.
4
Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies.路易体痴呆显性和前驱期生物学框架的意义与机遇
Alzheimers Dement. 2025 Jul;21(7):e70470. doi: 10.1002/alz.70470.
5
Disease progression from mild cognitive impairment to dementia for patients with Alzheimer's disease or Lewy body pathology.患有阿尔茨海默病或路易体病理的患者从轻度认知障碍发展为痴呆症的疾病进程。
J Alzheimers Dis Rep. 2025 Jul 10;9:25424823251359541. doi: 10.1177/25424823251359541. eCollection 2025 Jan-Dec.
6
Sex differences in prodromal dementia with Lewy bodies using the National Alzheimer's Coordinating Center data.利用美国国家阿尔茨海默病协调中心的数据研究路易体前驱性痴呆中的性别差异。
Alzheimers Dement. 2025 May;21(5):e70275. doi: 10.1002/alz.70275.
7
Key motor and non-motor features in early dementia with Lewy bodies.路易体痴呆早期的关键运动和非运动特征。
Front Neurol. 2025 Mar 13;16:1555175. doi: 10.3389/fneur.2025.1555175. eCollection 2025.
8
Validation of the neuropathological criteria of the fourth Consortium on dementia with Lewy Bodies in autopsy cases from psychiatric hospitals.对来自精神病医院尸检病例的路易体痴呆第四协作组神经病理学标准的验证。
Psychiatry Clin Neurosci. 2025 Jun;79(6):344-355. doi: 10.1111/pcn.13814. Epub 2025 Mar 31.
9
Longitudinal FDG-PET Metabolic Change Along the Lewy Body Continuum.路易体连续体中的纵向氟代脱氧葡萄糖正电子发射断层扫描代谢变化
JAMA Neurol. 2025 Mar 1;82(3):285-294. doi: 10.1001/jamaneurol.2024.4643.
10
Neuropsychological test performance in mild cognitive impairment with Lewy bodies: A systematic review and meta-analysis.路易体轻度认知障碍的神经心理学测试表现:一项系统评价和荟萃分析。
Alzheimers Dement. 2025 Feb;21(2):e14450. doi: 10.1002/alz.14450. Epub 2025 Jan 10.
前驱期路易体痴呆患者自主神经症状的频率、严重程度和持续时间。
J Alzheimers Dis. 2022;89(3):923-929. doi: 10.3233/JAD-220275.
4
Neuroimaging Biomarkers in a Patient With Probable Psychiatric-Onset Prodromal Dementia With Lewy Bodies.神经影像学生物标志物在一例可能以精神病发作为前驱的路易体痴呆患者中的应用。
Neurology. 2022 Oct 10;99(15):654-657. doi: 10.1212/WNL.0000000000201166.
5
Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort.路易体痴呆的前驱期特征:全国记忆诊所 MEMENTO 队列的基线结果。
Alzheimers Res Ther. 2022 Jul 19;14(1):96. doi: 10.1186/s13195-022-01037-0.
6
Elevated Plasma Orexin-A Levels in Prodromal Dementia with Lewy Bodies.路易体痴呆前驱期血浆食欲素-A 水平升高。
J Alzheimers Dis. 2022 Jun 14;88(3):1037-1048. doi: 10.3233/JAD-220082.
7
Detection of neuron-derived pathological α-synuclein in blood.血液中神经元衍生的病理性 α-突触核蛋白的检测。
Brain. 2022 Sep 14;145(9):3058-3071. doi: 10.1093/brain/awac115.
8
Sex Differences for Clinical Correlates of Alzheimer's Pathology in People with Lewy Body Pathology.路易体病患者阿尔茨海默病病理的临床相关性的性别差异。
Mov Disord. 2022 Jul;37(7):1505-1515. doi: 10.1002/mds.29044. Epub 2022 May 9.
9
Brain Metabolism Related to Mild Cognitive Impairment and Phenoconversion in Patients With Isolated REM Sleep Behavior Disorder.脑代谢与孤立性 REM 睡眠行为障碍患者轻度认知障碍及表型转化的关系。
Neurology. 2022 Jun 14;98(24):e2413-e2424. doi: 10.1212/WNL.0000000000200326. Epub 2022 Apr 18.
10
Blood pressure and heart rate responses to orthostatic challenge and Valsalva manoeuvre in mild cognitive impairment with Lewy bodies.路易体轻度认知障碍患者对直立性应激和瓦尔萨尔瓦动作的血压及心率反应
Int J Geriatr Psychiatry. 2022 May;37(5). doi: 10.1002/gps.5709.